PCV43 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
Abstract
Authors
P. Vorobyev L. Krasnova O. Borisenko D. Lukyantseva E. Bashlakova